SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  AM-Pharma: American Journal of Kidney Disease publishes review article of Alkaline Phosphatase

[January 28, 2014]

AM-Pharma: American Journal of Kidney Disease publishes review article of Alkaline Phosphatase

BUNNIK, the Netherlands --(Business Wire)--

AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that the American Journal of Kidney Disease has published an In Translation feature entitled: Alkaline phosphatase: a possible new treatment option for sepsis-associated acute kidney injury in critically ill patients.

AJKD's In Translation is a recurring education feature that is an authoritative review of science with diagnostic or therapeutic implications in clinical practise in nephrology. The authors of the article, (abstract available at: http://www.ajkd.org/article/S0272-6386(13)01636-3/abstract) are from Professor Pickkers' group, at the Department of Intensive Care Medicine, Nijmegen Institute for Infection, Inflammation and Immunity, Radboud University Nijmegen Medical Centre, The Neherlands.


He and his affiliates discuss the multi-factorial pathogenesis of sepsis-associated Acute Kidney Injury (AKI) and note that to be truly successful, an intervention would also need to address not a single but multiple targets.

They concluded that: "AP seems to be a promising new therapy for patients with sepsis-associated AKI because it restores an endogenously expressed protective enzyme that appears to exert a dual mechanism of action. AP may prevent the effects of inflammation and hypoxia, key events in the pathogenesis of sepsis-associated AKI. Therefore, AP seems to be a potent new treatment option for these patients."

The authors also noted that: "As inflammation and hypoxia are also involved in AKI induced by several other causes, including cardiac surgery and trauma, it would be of interest to further examine the therapeutic effects of AP in these additional clinical circumstances."

Commenting on the review paper, Erik van den Berg, CEO of AM-Pharma said, "It is satisfying and reassuring that an independent research group has come to similar conclusions to our research, on the potential of Alkaline Phosphatase to treat patients with a variety of AKI. We look forward to presenting further data on the clinical trials with recAP."

Notes for Editors

About AM-Pharma www.am-pharma.com

AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of acute kidney injury and inflammatory bowel diseases. AM-Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and a Phase II trial in Ulcerative Colitis - a form of inflammatory bowel disease - AM-Pharma developed an innovative recombinant form of human Alkaline Phosphatase. This recombinant Alkaline Phosphatase will be used in future trials and for commercialization. AM-Pharma raised €29.2M in Q4 2011, enabling AM-Pharma to finalize the GMP production and the development through phase II.

- ENDS -


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.